Direxion Daily S&P Biotech Bear 3X ETF
LABD
12 hedge funds and large institutions have $15.8M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
244% more call options, than puts
Call options by funds: $25.9M | Put options by funds: $7.53M
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
9% more funds holding
Funds holding: 11 → 12 (+1)
0.31% less ownership
Funds ownership: 0.38% → 0.06% (-0.31%)
45% less capital invested
Capital invested by funds: $28.7M → $15.8M (-$12.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.82M |
| 2 |
VF
Virtu Financial
New York
|
+$1.82M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.22M |
| 4 |
Jane Street
New York
|
+$727K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$547K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$1.29M |
| 2 |
Morgan Stanley
New York
|
-$465K |
| 3 |
Citigroup
New York
|
-$325K |
| 4 |
HIS
Harvest Investment Services
Oakbrook Terrace,
Illinois
|
-$279K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$208K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $7.95M | -$465K | -96 | -4% |
|
|
VF
2
Virtu Financial
New York
| $1.89M | +$1.82M | +375 | +268% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1.43M | +$1.22M | +252 | +184% |
|
|
BG
4
Bellevue Group
Kuesnacht,
Switzerland
| $1.38M | +$1.82M | +375 | New |
|
|
5
Jane Street
New York
| $881K | +$727K | +150 | +167% |
|
|
6
Citadel Advisors
Miami,
Florida
| $783K | -$208K | -43 | -17% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $424K | +$547K | +113 | +5,650% |
|
8
Simplex Trading
Chicago,
Illinois
| $374K | -$136K | -28 | -22% |
|
|
MMA
9
Miracle Mile Advisors
Los Angeles,
California
| $359K | +$325K | +67 | +216% |
|
|
10
Citigroup
New York
| $211K | -$325K | -67 | -54% |
|
|
WAM
11
Wolverine Asset Management
Chicago,
Illinois
| $121K | +$160K | +33 | New |
|
12
UBS Group
Zurich,
Switzerland
| $31K | +$38.7K | +8 | New |
|
|
TCM
13
Traynor Capital Management
Malvern,
Pennsylvania
| – | -$1.29M | -151 | Closed |
|
|
HIS
14
Harvest Investment Services
Oakbrook Terrace,
Illinois
| – | -$279K | -49 | Closed |
|
LABD Hedge Fund Activity: Q1 2019 in Review
12 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2019, worth a combined $15.8M — down 45% from $28.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LABD positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $1.82M. The largest seller was Traynor Capital Management, exiting entirely with an estimated $1.29M sold.
- 12 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2019, up from 11 in Q4 2018.
- Funds reported $15.8M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2019, down 45% quarter-over-quarter.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2019 and 2 closed out, a net change of +1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2019 was Bellevue Group, an estimated $1.82M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2019 was Traynor Capital Management, an estimated $1.29M sold.
Based on aggregated 13F filings for Q1 2019.